Vyosov belongs to Cipla now

▴ Cipla
Cipla Ltd.has acquired the brand name and trademark rights for Vysov of the anti-diabetic drug, Vildagliptin for the Indian market.

Cipla Ltd.has acquired the brand name and trademark rights for Vysov of the anti-diabetic drug, Vildagliptin for the Indian market. The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov® & Vysov M® and has witnessed a strong uptake for the product in India for the last couple of years. It is currently available across the country.

Vildagliptin is an orally active, potent and selective DPP-4 inhibitor that improves glycemic control in patients primarily by enhancing pancreatic (α and β) islet functions. The drug is backed by strong clinical data & is, therefore, a widely prescribed antidiabetic medicine for adults with type 2 diabetes mellitus.

The current market size of Vildagliptin is INR 818 Cr. as per IQVIA MAT Nov’ 2019 in India. Mr Nikhil Chopra, Executive Vice-President & Head India Business, Cipla Ltd. said “Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla’s acquisition of the trademark rights of Vysov® will enable us to contribute to easier access to the drug in India.”

Tags : #cipla #trademark #pancreasdrug #acquisition #vyosov #drug #healthcare #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024